Lung adenocarcinoma

2 trials 1 recruiting MedDRA PT
2 Registered trials
1 Recruiting
2 Unique sponsors
1 Unique IMPs
2 Commercial trials
Drug classes (ATC)
ATC code not specified 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
Phase II: 1 Phase I: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase II

1 trial
  • Boehringer Ingelheim International GmbH Commercial
    (3S,3'S,3A'S,10A'S)-6-CHLORO-3'-(3-CHLORO-2-FLUOROPHENYL)-1'-(CYCLOPROPYLMETHYL)-6'-METHYL-2-OXO-1,2,3',3A',10',10A'-HEXAHYDRO-1'H-SPIRO[INDOLE-3,2'-PYRROLO[2',3':4,5]PYRROLO[1,2-B]INDAZOLE]-7'-CARBOXYLIC ACID
    2023-506369-79-00 5 countries 2022 n=38
    Ended

Phase I

1 trial
  • BeOne Medicines AG Commercial
    IMP not specified
    2023-506888-34-00 1 country 2024 n=91
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
BeOne Medicines AG Commercial 1 Phase I 1
Boehringer Ingelheim International GmbH Commercial 1 Phase II 0
New trials by year
2022
1
2024
1
← All indication landscapes